Cathepsin D expression by cancer and stromal cells in breast cancer: an immunohistochemical study of 1348 cases.
This study was aimed at investigating the influence of cathepsin D (CD) expression by cancer cells and stromal cells on breast cancer prognosis. This is a study of 1348 node-positive (NPBC) and node-negative (NNBC) breast cancers diagnosed between 1980 and 1986 and with a minimum follow-up of 5.2 years. CD expression was assessed by immunohistochemistry on archival material using a polyclonal antibody. The expression by cancer and stromal cells was assessed separately and correlated with distant metastasis free (DMFS) and overall survival (OS). Cancer cells expressed CD (more than 10% cells expressing CD) in 38.9% of cases and reactive stromal cells in 43.6%. CD expression by reactive stromal cells, and not cancer cells, correlated with several factors of poor prognosis by cancer cells. A strong association was also found with expression of other proteases (stromelysin-3, gelatinase A, and urokinase Plasminogen Activator) by these same reactive stromal cells. CD expression by cancer cells did not predict DMFS or OS but, by univariate analysis, CD expression by reactive stromal cells was associated with earlier recurrence and shorter survival in NNBC (p = 0.0425) and NPBC patients submitted to adjuvant chemotherapy (p = 0.0234). However, CD expression by reactive stromal cells remained a significant predictor of recurrence by multivariate analyses only in a subgroup of NPBC submitted to adjuvant chemotherapy. Overall, those data support the concept that proteases produced by reactive stromal cells are under cancer cell stimulation and that CD by stromal cells, and not cancer cells, influences the prognosis, but only in a subgroup of patients with breast cancer.
Têtu
B
B
Department of Pathology, Université Laval, Québec, Canada. Bernard.Tetu@crhdq.ulaval.ca
Brisson
J
J
Lapointe
H
H
Wang
C S
CS
Bernard
P
P
Blanchette
C
C
D000230:Adenocarcinoma / Q000737:chemistry / Q000201:enzymology / Q000235:genetics / Q000401:mortality / Q000473:pathology; D000328:Adult; D000368:Aged; D014408:Biomarkers, Tumor / Q000032:analysis / Q000096:biosynthesis* / Q000235:genetics; D001943:Breast Neoplasms / Q000737:chemistry / Q000201:enzymology* / Q000235:genetics / Q000401:mortality; D018270:Carcinoma, Ductal, Breast / Q000737:chemistry / Q000201:enzymology / Q000235:genetics / Q000401:mortality / Q000473:pathology; D002402:Cathepsin D / Q000096:biosynthesis* / Q000235:genetics; D002452:Cell Count; D018572:Disease-Free Survival; D010450:Endopeptidases / Q000096:biosynthesis / Q000235:genetics; D004790:Enzyme Induction; D005260:Female; D019084:Fluorescent Antibody Technique, Indirect; D006801:Humans; D007124:Immunoenzyme Techniques; D015993:Life Tables; D008207:Lymphatic Metastasis; D008264:Macrophages / Q000473:pathology; D008875:Middle Aged; D009363:Neoplasm Proteins / Q000032:analysis / Q000096:biosynthesis* / Q000235:genetics; D014411:Neoplastic Stem Cells / Q000201:enzymology*; D011379:Prognosis; D011792:Quebec / Q000453:epidemiology; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000032:analysis; D011960:Receptors, Estrogen / Q000032:analysis; D011980:Receptors, Progesterone / Q000032:analysis; D012189:Retrospective Studies; D012307:Risk Factors; D017154:Stromal Cells / Q000201:enzymology*; D016019:Survival Analysis; D016159:Tumor Suppressor Protein p53 / Q000032:analysis
D014408:Biomarkers, Tumor; D002402:Cathepsin D; D010450:Endopeptidases; D009363:Neoplasm Proteins; D018719:Erb-b2 Receptor Tyrosine Kinases; D011960:Receptors, Estrogen; D011980:Receptors, Progesterone; D016159:Tumor Suppressor Protein p53